Back to Journals » OncoTargets and Therapy » Volume 17

Pharmacological Inhibition of Necroptosis Promotes Human Breast Cancer Cell Proliferation and Metastasis [Retraction]

Authors Shen F, Pan X, Li M , Chen Y , Jiang Y , He J 

Received 27 June 2024

Accepted for publication 27 June 2024

Published 3 July 2024 Volume 2024:17 Pages 541—542

DOI https://doi.org/10.2147/OTT.S484569



Shen F, Pan X, Li M, Chen Y, Jiang Y, He J. Onco Targets Ther. 2020;13:3165–3176.

We, the Editor and Publisher of the journal OncoTargets and Therapy have retracted the published article.

Following publication of the article, the authors raised concerns about the duplication of images from Figures 5 and 6. Specifically,

  • The images for Figure 5B, Veh and Nec-1, 0h, have been duplicated.
  • The images for Figure 6A and 6B, MCF-7, Nec-1, have been duplicated.

The authors were cooperative and were able to provide some original data for the study but were unable to provide a satisfactory explanation for how the images came to be duplicated. As verifying the validity of published work is core to the integrity of the scholarly record, the Publisher and Editor requested to retract the article and the authors do not agree with this decision.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.


This retraction relates to this paper


Creative Commons License © 2024 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.